AltMountain

Avoro Capital Advisors LLC

New York, NY · CRD 154091
Hedge fund manager

Avoro Capital Advisors LLC is an SEC-registered investment adviser based in New York, NY that reports managing 1 hedge fund on Form ADV. It reports $13.6 billion in regulatory assets under management. Its private funds, of all types, hold $13.6 billion in gross assets. Its disclosed U.S. stock holdings returned an estimated +21.5% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +81.9% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.

Regulatory assets under management
$13.6 billionForm ADV Item 5.F
Gross assets of private funds
$13.6 billionAll private fund types, Form ADV
Hedge funds managed
12 private funds in total
Employees
19Form ADV Item 5.A
Registration
SEC-registered adviserCRD 154091
Latest Form ADV
03/05/2026Disciplinary disclosures: none reported

Estimated 13F portfolio performance

Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.

Estimated from 13F · 2026 YTD+21.5%Through Q2 2026 · S&P 500 +9.5%
Estimated from 13F · 2 years+81.9%Q3 2024 – Q2 2026
S&P 500+37.2%Same quarters, price only
13F holdings$11.1 billion26 positions, 2026-06-30
$92$137$182Q3 2024Q1 2025Q3 2025Q1 202613F est. $182S&P 500 $137
QuarterEst. 13F returnS&P 500
Q2 2026+18.8%+14.8%
Q1 2026+2.3%-4.6%
Q4 2025+22.2%+2.4%
Q3 2025+33.1%+7.8%
Q2 2025-0.9%+10.4%
Q1 2025-7.2%-4.5%
Q4 2024-2.5%+2.1%
Q3 2024+2.6%+5.4%

Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures

Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.

13F holdings as of Sep 30, 2026

All 30 share positions ($9,690,900,114) reported by Avoro Capital Advisors LLC on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.

Share of the reported 13F portfolio, ten largest positions

  • United Therapeutics Corp Del15.41%
  • Ascendis Pharma A/s11.87%
  • Krystal Biotech Inc9.91%
  • Argenx SE9.89%
  • Madrigal Pharmaceuticals Inc9.53%
  • Kymera Therapeutics Inc8.62%
  • Arrowhead Pharmaceuticals In7.43%
  • Revolution Medicines Inc4.54%
  • Cytokinetics Inc3.33%
  • Definium Therapeutics Inc2.77%
StockValue% of 13F portfolioSharesShares vs prior quarter
United Therapeutics Corp Del$1,493,207,69915.41%2,755,555-0.80%
Ascendis Pharma A/s$1,150,541,50011.87%5,050,000-1.20%
Krystal Biotech Inc$960,728,5939.91%2,888,888Unchanged
Argenx SE$958,910,0009.89%1,000,000Unchanged
Madrigal Pharmaceuticals Inc$923,926,4999.53%1,833,333Unchanged
Kymera Therapeutics Inc$835,601,9678.62%7,474,747Unchanged
Arrowhead Pharmaceuticals In$719,950,0007.43%11,000,000-3.13%
Revolution Medicines Inc$440,282,7004.54%2,145,000-6.62%
Cytokinetics Inc$322,959,0003.33%4,900,000-2.00%
Definium Therapeutics Inc$268,323,0002.77%7,050,000-1.93%
Structure Therapeutics Inc$204,992,2052.12%6,555,555Unchanged
Xenon Pharmaceuticals Inc$204,545,0002.11%5,500,000-4.81%
Vera Therapeutics Inc$181,954,1501.88%5,635,000-1.55%
Uniqure NV$162,543,0921.68%6,727,777Unchanged
Celcuity Inc$119,280,0001.23%1,500,000-55.88%
Taysha Gene Therapies Inc$116,338,8851.20%23,888,888Unchanged
Ocular Therapeutix Inc$94,956,9010.98%12,380,300-1.27%
Damora Therapeutics Inc Com SHS$80,502,2400.83%3,783,000New
Hemab Therapeutics Hldgs Inc$58,360,7520.60%1,892,372-1.70%
Viridian Therapeutics Inc$51,475,0000.53%2,500,000Unchanged
Septerna Inc$50,869,0000.52%1,300,000-2.80%
Abivax SA$48,321,7600.50%488,000New
Scribe Therapeutics Inc$47,834,0980.49%2,598,973New
Faeth Therapeutics Inc$41,933,4000.43%1,410,000-2.36%
GH Research PLC$41,559,6000.43%1,770,000-1.67%
Biohaven Pharmaceutical Holding Co. LTD$36,712,5000.38%2,750,000New
Avalo Therapeutics Inc$36,451,3210.38%2,377,777+1.90%
Braveheart Bio Inc$25,351,0000.26%1,255,000New
Whitehawk Therapeutics Inc$10,713,7520.11%2,849,402Unchanged
Lexeo Therapeutics Inc$1,774,5000.02%525,000-64.75%

Changes since Jun 30, 2026

Comparing the share counts in the two quarter-end filings: 5 new positions, 1 sold out, 1 increased, 15 reduced and 9 unchanged.

Number of positions (a count, not dollars)

  • New positions5
  • Increased1
  • Unchanged9
  • Reduced15
  • Sold out1

New positions

StockValueShares
Damora Therapeutics Inc Com SHS$80,502,2403,783,000
Abivax SA$48,321,760488,000
Scribe Therapeutics Inc$47,834,0982,598,973
Biohaven Pharmaceutical Holding Co. LTD$36,712,5002,750,000
Braveheart Bio Inc$25,351,0001,255,000

Sold out

StockValue at Jun 30, 2026Shares held then
Damora Therapeutics Inc$98,395,8303,783,000

Largest increases

StockChange in sharesChangeValue nowShares now
Avalo Therapeutics Inc+44,444+1.90%$36,451,3212,377,777

Largest reductions

StockChange in sharesChangeValue nowShares now
Celcuity Inc-1,900,000-55.88%$119,280,0001,500,000
Revolution Medicines Inc-152,000-6.62%$440,282,7002,145,000
Arrowhead Pharmaceuticals In-355,555-3.13%$719,950,00011,000,000
Ascendis Pharma A/s-61,111-1.20%$1,150,541,5005,050,000
United Therapeutics Corp Del-22,222-0.80%$1,493,207,6992,755,555
Xenon Pharmaceuticals Inc-277,777-4.81%$204,545,0005,500,000
Cytokinetics Inc-99,999-2.00%$322,959,0004,900,000
Definium Therapeutics Inc-138,888-1.93%$268,323,0007,050,000
Lexeo Therapeutics Inc-964,189-64.75%$1,774,500525,000
Vera Therapeutics Inc-88,888-1.55%$181,954,1505,635,000
Septerna Inc-37,500-2.80%$50,869,0001,300,000
Ocular Therapeutix Inc-159,700-1.27%$94,956,90112,380,300
Faeth Therapeutics Inc-34,039-2.36%$41,933,4001,410,000
Hemab Therapeutics Hldgs Inc-32,778-1.70%$58,360,7521,892,372
GH Research PLC-30,000-1.67%$41,559,6001,770,000

Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.

From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures

Large ownership stakes (Schedule 13D and 13G)

CompanyFilingPercent of classSharesFiledSource
Celcuity Inc.13G amendment3.07%1,500,000Nov 16, 2026SEC.gov ↗
Vera Therapeutics, Inc.13G amendment7.82%5,635,000Nov 16, 2026SEC.gov ↗
Faeth Therapeutics, Inc.13G5.46%1,410,000Nov 16, 2026SEC.gov ↗
Hemab Therapeutics Holdings, Inc.13G4.12%1,925,150Aug 14, 2026SEC.gov ↗
Arrowhead Pharmaceuticals, Inc.13G amendment9.64%13,823,383Aug 14, 2026SEC.gov ↗
Avalo Therapeutics, Inc.13G amendment4.44%2,333,333Aug 14, 2026SEC.gov ↗
Scribe Therapeutics, Inc.13D13.78%2,598,973Jul 30, 2026SEC.gov ↗
Centessa Pharmaceuticals plc13G amendment7.39%11,430,455May 15, 2026SEC.gov ↗
Soleno Therapeutics Inc13G amendment4.45%2,300,000May 15, 2026SEC.gov ↗
Xenon Pharmaceuticals, Inc.13G amendment6.26%5,777,777May 15, 2026SEC.gov ↗
Damora Therapeutics, Inc.13G6.27%3,783,000May 15, 2026SEC.gov ↗
Whitehawk Therapeutics, Inc.13D amendment19.99%15,893,516May 14, 2026SEC.gov ↗
uniQure N.V.13G amendment9.87%6,150,000Feb 17, 2026SEC.gov ↗
Avidity Biosciences, Inc.13G amendment5.54%8,515,792Feb 17, 2026SEC.gov ↗
Definium Therapeutics, Inc.13G5.08%5,000,000Feb 17, 2026SEC.gov ↗

A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Nov 14, 2025, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Showing the 15 most recent of 19 companies. Source: U.S. Securities and Exchange Commission, EDGAR.

Hedge funds filing Form D (2)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

Private funds reported on Form ADV (2)

Fund
Gross assets
Minimum
Owners
Adviser
Avoro Life Sciences Fund LLC
Delaware, United StatesHedge fund
Gross assets$8.6B
Minimum$1.0M
Owners405
AdviserAvoro Capital Advisors LLC
Avoro Ventures Fund L.P.
Delaware, United StatesVenture capital fund
Gross assets$166M
Minimum$5.0M
Owners48
AdviserAvoro Capital Advisors LLC

As reported in the adviser's Form ADV filed Jun 4, 2024. Funds also listed from Form D are shown above.

From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures⁠​​‌‌‌‌‌‌‌​‌‌‌‌‌‌‌‌‌‌⁠